Integra LifeSciences (NASDAQ:IART) Releases Earnings Results, Beats Estimates By $0.03 EPS

Integra LifeSciences (NASDAQ:IART) issued its quarterly earnings data on Wednesday. The life sciences company reported $0.59 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.56 by $0.03, FiscalAI reports. The company had revenue of $411.18 million for the quarter, compared to analyst estimates of $413.16 million. Integra LifeSciences had a negative net margin of 0.44% and a positive return on equity of 18.30%. During the same period last year, the company posted ($0.07) earnings per share.

Here are the key takeaways from Integra LifeSciences’ conference call:

• Cincinnati disruption worsened, reducing third-quarter revenue by approximately $7 million and expected to cut fourth-quarter revenue by another $15 million-$20 million. Full manufacturing operations for the MAYFIELD product family are not expected until the second quarter of 2027.
• Specialty Surgery remained resilient, with organic revenue growth of 4.2% and neurosurgery growth of 6.5% despite the Cincinnati headwind. Management cited continued momentum in CereLink, Certas Plus, Bactiseal, DuraSeal, cranial perforators, and international markets.
• Tissue Reconstruction declined 2.2% organically, pressured by MicroMatrix/UBM competition and slower share recovery for certain Integra Skin products. Management expects base Tissue Reconstruction revenue to remain approximately flat in 2027, although SurgiMend should provide incremental growth after its planned December relaunch.
• Cash generation and balance-sheet flexibility improved, with record quarterly operating cash flow of $96 million, leverage reduced to 3.8 times, and $46 million of debt repaid. The completed $2.1 billion refinancing extends maturities and increases covenant capacity, though it will add approximately $24 million of annual interest expense in 2027.
• Full-year 2026 guidance remains revenue of $1.634 billion-$1.654 billion and adjusted EPS of $2.30-$2.40, while fourth-quarter revenue is expected to decline year over year at the midpoint. Management expects 2027 revenue and EPS growth, but acknowledged headwinds from Cincinnati, tariffs, higher interest expense, and slower Tissue Reconstruction recovery.

Integra LifeSciences Trading Down 11.2%

Shares of NASDAQ:IART opened at $11.84 on Thursday. Integra LifeSciences has a 52-week low of $8.70 and a 52-week high of $20.49. The business has a 50-day moving average price of $15.56 and a 200-day moving average price of $15.56. The company has a quick ratio of 2.11, a current ratio of 3.60 and a debt-to-equity ratio of 1.75. The stock has a market cap of $920.80 million, a price-to-earnings ratio of -131.54, a PEG ratio of 0.71 and a beta of 1.21.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on IART. Wells Fargo & Company set a $15.00 target price on Integra LifeSciences in a research report on Saturday, October 3rd. Truist Financial reduced their price target on Integra LifeSciences from $19.00 to $15.00 and set a “hold” rating for the company in a research report on Wednesday, October 14th. Wall Street Zen lowered Integra LifeSciences from a “buy” rating to a “hold” rating in a research report on Saturday, October 3rd. Weiss Ratings cut Integra LifeSciences from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, October 2nd. Finally, BMO Capital Markets decreased their price objective on Integra LifeSciences from $18.00 to $15.00 and set a “market perform” rating for the company in a research note on Monday, October 5th. Two analysts have rated the stock with a Buy rating, four have assigned a Hold rating and two have given a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $16.71.

Integra LifeSciences News Roundup

Here are the key news stories impacting Integra LifeSciences this week:

• Positive Sentiment: Integra reported third-quarter adjusted earnings of $0.59 per share, above the $0.56 analyst consensus and up from $0.54 a year earlier. GAAP earnings also improved to $0.19 per share from a prior-year loss of $0.07. Integra LifeSciences Surpasses Q3 Earnings Estimates
• Positive Sentiment: Operating cash flow reached $96 million, net debt declined to approximately $1.52 billion, and the leverage ratio improved to 3.8x. Integra also completed a $2.1 billion refinancing that extends maturities and provides additional covenant flexibility. Integra LifeSciences Refinancing
• Neutral Sentiment: Third-quarter revenue increased 2.3% to $411.2 million, but fell short of the $413.2 million consensus estimate. Specialty Surgery grew 3.9%, while Tissue Reconstruction revenue declined 2.2%.
• Negative Sentiment: Integra forecast fourth-quarter revenue of $413 million to $433 million, implying a year-over-year decline of as much as 5.2%. Management cited the Cincinnati facility flood and continued softness in Tissue Reconstruction; the disruption reduced quarterly revenue by roughly $7 million. Integra Life Falls on Q3 Revenue Miss
• Negative Sentiment: The refinancing strengthens liquidity but is expected to increase Integra’s effective interest rate near the high end of its previously indicated range, adding pressure to earnings and cash flow. Truist also lowered its price target from $19 to $15. Truist Cuts Integra Price Target
• Negative Sentiment: A securities-law firm announced an investigation into possible violations involving Integra and its senior management. The announcement is an investor solicitation and does not establish wrongdoing, but it adds reputational and legal overhang. Integra Investor Investigation

About Integra LifeSciences

Integra LifeSciences Holdings Corporation (NASDAQ:IART) is a global medical technology company that develops and manufactures products used in neurosurgery, reconstructive surgery, orthopedics and wound care. Its portfolio includes medical devices, surgical instruments and regenerative tissue technologies designed to help healthcare professionals treat complex conditions and support patient recovery.

Integra’s neurosurgical products include dural repair products, cerebrospinal fluid management systems, cranial stabilization devices and specialized surgical instruments.